Your browser doesn't support javascript.
loading
Community participatory learning and action cycle groups to reduce type 2 diabetes in Bangladesh (D:Clare): an updated study protocol for a parallel arm cluster randomised controlled trial.
King, Carina; Pires, Malini; Ahmed, Naveed; Akter, Kohenour; Kuddus, Abdul; Copas, Andrew; Haghparast-Bidgoli, Hassan; Morrison, Joanna; Nahar, Tasmin; Shaha, Sanjit Kumer; Khan, AKAzad; Azad, Kishwar; Fottrell, Edward.
Afiliação
  • King C; Institute for Global Health, University College London, 30 Guildford Street, London, WC1N 1EH, UK.
  • Pires M; Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.
  • Ahmed N; Institute for Global Health, University College London, 30 Guildford Street, London, WC1N 1EH, UK.
  • Akter K; Diabetic Association of Bangladesh, Dhaka, Bangladesh.
  • Kuddus A; Diabetic Association of Bangladesh, Dhaka, Bangladesh.
  • Copas A; Diabetic Association of Bangladesh, Dhaka, Bangladesh.
  • Haghparast-Bidgoli H; Institute for Global Health, University College London, 30 Guildford Street, London, WC1N 1EH, UK.
  • Morrison J; Institute for Global Health, University College London, 30 Guildford Street, London, WC1N 1EH, UK.
  • Nahar T; Institute for Global Health, University College London, 30 Guildford Street, London, WC1N 1EH, UK.
  • Shaha SK; Diabetic Association of Bangladesh, Dhaka, Bangladesh.
  • Khan A; Diabetic Association of Bangladesh, Dhaka, Bangladesh.
  • Azad K; Diabetic Association of Bangladesh, Dhaka, Bangladesh.
  • Fottrell E; Diabetic Association of Bangladesh, Dhaka, Bangladesh.
Trials ; 24(1): 218, 2023 Mar 23.
Article em En | MEDLINE | ID: mdl-36959617
The "Diabetes: Community-led Awareness, Response and Evaluation" (D:Clare) trial aims to scale up and replicate an evidence-based participatory learning and action cycle intervention in Bangladesh, to inform policy on population-level T2DM prevention and control.The trial was originally designed as a stepped-wedge cluster randomised controlled trial, with the interventions running from March 2020 to September 2022. Twelve clusters were randomly allocated (1:1) to implement the intervention at months 1 or 12 in two steps, and evaluated through three cross-sectional surveys at months 1, 12 and 24. However, due to the COVID-19 pandemic, we suspended project activities on the 20th of March 2020. As a result of the changed risk landscape and the delays introduced by the COVID-19 pandemic, we changed from the stepped-wedge design to a wait-list parallel arm cluster RCT (cRCT) with baseline data. We had four key reasons for eventually agreeing to change designs: equipoise, temporal bias in exposure and outcomes, loss of power and time and funding considerations.Trial registration ISRCTN42219712 . Registered on 31 October 2019.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / COVID-19 Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Humans País/Região como assunto: Asia Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / COVID-19 Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Humans País/Região como assunto: Asia Idioma: En Ano de publicação: 2023 Tipo de documento: Article